| (210) | Number of the EPO application | 18728153 |
| (220) | Filing date of the EPO application | 2018.05.30 |
| (80) | EPO patent specification publication (B) | EPB nr. 32/2023, 2023.08.09 |
| (110) | EPO patent number | 3630177 |
| (11) | Number of the document | MD 3630177 T2 |
| (21) | Number of the application | e 2020 0316 |
| (71) | Name(s) of applicant(s), code of the country | MORPHOSYS AG, DE; |
| (72) | Name(s) of inventor(s), code of the country | KELEMEN Peter, DE;
SCHWARZ Michael, DE;
WINDERLICH Mark, DE;
HEEGER Steffen, DE;
WEINELT Dominika, DE; |
| (73) | Name(s) of owner(s), code of the country | MORPHOSYS AG, DE; |
| (54) | Title of the invention | Treatment paradigm for an anti-CD19 antibody and venetoclax combination treatment |
| (13) | Kind-of-document code | T2 |
| (51) | International Patent Classification | A61K 39/395 (2006.01.01); A61K 31/00 (2006.01.01); C07K 16/28 (2006.01.01); A61P 35/00 (2006.01.01) |
| (19) | Country | DE |
| (41) | Date of publication of the application | 2020.05.31 |
| (49) | Date of publication of the translation of the validated European patent specification | 2024.01.31 |
| (30) | Priority | 17173712, 2017.05.31, EP |
| (74) | Patent attorney | (Procedură) PARASCA Dumitru, str. Eminescu nr. 40, ap. 13, c/p 28, MD-2012, Chişinău, Republica Moldova |
| (86) | International application | PCT/EP2018/064229, 2018.05.30 |
| (87) | International publication | WO 2018/220040, 2018.12.06 |